ENZ - Enzo Biochem, Inc.
NYSE
->
Healthcare
->
Diagnostics & Research
New York,
United States
Type: Equity
ENZ price evolution
ENZ
| (in millions $) | 2 Mar 2024 | 1 Dec 2023 | 31 Aug 2023 | 30 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $60.24 | $69.21 | $82.37 | |
| Short term investments | ||||
| Net receivables | $5.12 | $4.18 | $4.81 | $9.64 |
| Inventory | $7.8 | $7.59 | $7.94 | $15.29 |
| Total current assets | $80.92 | $88.01 | $98.46 | $32 |
| Long term investments | ||||
| Property, plant & equipment | $16.02 | $16.48 | $16.71 | $30.96 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $18.16 | $18.3 | $23.42 | |
| Total investments | ||||
| Total assets | $99.08 | $106.31 | $121.88 | $72.06 |
| Current liabilities | ||||
| Accounts payable | $1.32 | $1.96 | $3.58 | $13.64 |
| Deferred revenue | ||||
| Short long term debt | $4.09 | $3.76 | $3.49 | |
| Total current liabilities | $25.28 | $28.84 | $39.99 | $42.15 |
| Long term debt | $0.23 | $0.22 | $0.27 | $0.25 |
| Total noncurrent liabilities | $3.02 | $3.19 | $3.43 | |
| Total debt | $7.11 | $6.95 | $6.92 | |
| Total liabilities | $28.3 | $32.03 | $43.42 | $53.13 |
| Shareholders' equity | ||||
| Retained earnings | -$278.03 | -$274.97 | -$268.35 | -$325.78 |
| Other shareholder equity | $2.05 | $2.75 | $1.88 | $2.16 |
| Total shareholder equity | $70.78 | $74.28 | $78.46 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $82.37 | $21.6 | $13.52 | $47.87 |
| Short term investments | $29.98 | |||
| Net receivables | $4.81 | $11.52 | $10.2 | $9.14 |
| Inventory | $7.94 | $15.41 | $12.65 | $7.78 |
| Total current assets | $98.46 | $54.35 | $70.58 | $68.77 |
| Long term investments | ||||
| Property, plant & equipment | $16.71 | $32.43 | $33.6 | $34.4 |
| Goodwill & intangible assets | $7.45 | $7.7 | $7.99 | |
| Total noncurrent assets | $23.42 | $41.5 | $43.11 | $43.77 |
| Total investments | $29.98 | |||
| Total assets | $121.88 | $95.86 | $113.69 | $112.54 |
| Current liabilities | ||||
| Accounts payable | $3.58 | $8.51 | $8.12 | $8.5 |
| Deferred revenue | ||||
| Short long term debt | $3.49 | $3.74 | $3.65 | $11.46 |
| Total current liabilities | $39.99 | $24.55 | $26.08 | $32.8 |
| Long term debt | $3.43 | $16.84 | $19.03 | $21.36 |
| Total noncurrent liabilities | $3.43 | $16.84 | $19.03 | $21.36 |
| Total debt | $6.92 | $20.59 | $22.68 | $32.82 |
| Total liabilities | $43.42 | $41.4 | $45.1 | $54.16 |
| Shareholders' equity | ||||
| Retained earnings | -$268.35 | -$288.64 | -$270.38 | -$278.25 |
| Other shareholder equity | $1.88 | $3.15 | $1.35 | $1.68 |
| Total shareholder equity | $78.46 | $54.46 | $68.59 | $58.38 |
| (in millions $) | 2 Mar 2024 | 1 Dec 2023 | 31 Aug 2023 | 30 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.55 | $7.81 | $31.06 | $16.11 |
| Cost of revenue | ||||
| Gross Profit | $4.22 | $3.46 | $11.57 | $1.64 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $5.65 | $7.86 | $31.11 | $13 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $1.59 | -$0.03 | $0.16 | $0.31 |
| Net income | ||||
| Net income | -$3.06 | -$6.62 | $20.29 | -$15.19 |
| Income (for common shares) | ||||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $31.06 | $107.07 | $117.73 | $76.02 |
| Cost of revenue | $19.5 | $65.1 | $64.15 | $52.25 |
| Gross Profit | $11.57 | $41.97 | $53.58 | $23.77 |
| Operating activities | ||||
| Research & development | $3.9 | $3.77 | $3.25 | $4.45 |
| Selling, general & administrative | $32.4 | $53.71 | $49.63 | $49.69 |
| Total operating expenses | $36.3 | $56.97 | $52.88 | $54.14 |
| Operating income | -$24.74 | -$15.01 | $0.69 | -$30.37 |
| Income from continuing operations | ||||
| EBIT | $21.41 | -$18.42 | $7.87 | -$28.97 |
| Income tax expense | ||||
| Interest expense | $1.12 | -$0.16 | -$0.01 | -$0.45 |
| Net income | ||||
| Net income | $20.29 | -$18.26 | $7.88 | -$28.52 |
| Income (for common shares) | $20.29 | -$18.26 | $7.88 | -$28.52 |
| (in millions $) | 2 Mar 2024 | 1 Dec 2023 | 31 Aug 2023 | 30 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.28 | -$0.25 | $98.98 | -$2.19 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.54 | -$0.52 | -$1.13 | $3.12 |
| Effect of exchange rate | -$0 | -$0.02 | -$0.11 | $0.05 |
| Change in cash and equivalents | -$23.13 | -$14.17 | $60.77 | -$18.97 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $20.29 | -$18.26 | $7.88 | -$28.52 |
| Operating activities | ||||
| Depreciation | $2.68 | $2.83 | $2.65 | $2.78 |
| Business acquisitions & disposals | $101.74 | |||
| Stock-based compensation | $3.15 | $2.34 | $1.64 | $1.77 |
| Total cash flows from operations | -$36.98 | -$16.59 | $0.39 | -$17.18 |
| Investing activities | ||||
| Capital expenditures | -$2.76 | -$3.47 | -$4.44 | -$2.17 |
| Investments | $28.7 | -$30.06 | ||
| Total cash flows from investing | $98.98 | $25.22 | -$34.5 | -$2.17 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.4 | $0.03 | $0.1 | |
| Net borrowings | -$1.52 | -$0.27 | -$0.34 | $7 |
| Total cash flows from financing | -$1.13 | -$0.24 | -$0.24 | $7 |
| Effect of exchange rate | -$0.11 | -$0.06 | $0.01 | $0.07 |
| Change in cash and equivalents | $60.77 | $8.33 | -$34.34 | -$12.28 |
News
Fundamentals
| Market cap | $54.02M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 50.49M |
| Revenue | $63.53M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$4.58M |
| Revenue Q/Q | -47.65% |
| Revenue Y/Y | -19.77% |
| P/E ratio | -11.81 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.85 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.09 |
|---|---|
| ROA | -4.58% |
| ROE | N/A |
| Debt/Equity | 0.55 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.20 |
| Quick ratio | 2.89 |